Dynorphin Relieves Pain AND Prevents the Body From Building Tolerance to Morphine

Dynorphin injected into rat brains produced dose-dependent pain relief and prevented acute morphine tolerance, suggesting it could help maintain morphine's effectiveness.

Kishioka, S et al.·Japanese journal of pharmacology·1992·Preliminary EvidenceAnimal StudyAnimal Study
RPEP-00240Animal StudyPreliminary Evidence1992RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Animal Study
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

Dynorphin(1-13) ICV produced dose-dependent antinociception. It prevented acute morphine tolerance development. Potency order: beta-endorphin > morphine > dynorphin >> met-enkephalin.

Key Numbers

How They Did This

Male rats received ICV dynorphin(1-13) at various doses. Pain was tested using hind paw pressure and acetic acid writhing. Morphine tolerance was assessed by repeated dosing with and without prior dynorphin.

Why This Research Matters

If dynorphin prevents morphine tolerance, it could be used alongside morphine to maintain pain relief in chronic pain patients without needing increasing doses.

The Bigger Picture

Morphine tolerance is a major problem in chronic pain management — patients need ever-increasing doses. If dynorphin can prevent this tolerance, it could fundamentally improve how opioid pain medications are used long-term.

What This Study Doesn't Tell Us

Animal study with brain injection. High doses needed for pain relief raise questions about practicality. Acute tolerance prevention may not translate to chronic use.

Questions This Raises

  • ?Could dynorphin-based drugs be combined with morphine in clinical pain management?
  • ?Does dynorphin prevent chronic tolerance as well as acute tolerance?

Trust & Context

Key Stat:
Prevented tolerance Dynorphin co-administration stopped the development of acute morphine tolerance in rats
Evidence Grade:
Preliminary — animal study using intracerebroventricular injection. Shows promising mechanism but requires high doses and has not been tested chronically.
Study Age:
Published in 1992 (34 years ago). Opioid tolerance prevention remains a major research goal; kappa-mu interactions continue to be studied.
Original Title:
Dynorphin-(1-13): antinociceptive action and its effects on morphine analgesia and acute tolerance.
Published In:
Japanese journal of pharmacology, 60(3), 197-207 (1992)
Database ID:
RPEP-00240

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Tests effects in animals (usually mice or rats), not humans.

What do these levels mean? →

Frequently Asked Questions

What is morphine tolerance?

Tolerance means the body adapts to morphine so that the same dose produces less pain relief over time. Patients need increasing doses, raising risks of addiction and overdose. Preventing tolerance would be a major breakthrough.

How does dynorphin prevent tolerance?

The exact mechanism isn't fully clear, but dynorphin acts on kappa opioid receptors while morphine acts on mu receptors. The interaction between these two receptor systems appears to block the cellular changes that cause tolerance.

Read More on RethinkPeptides

Cite This Study

RPEP-00240·https://rethinkpeptides.com/research/RPEP-00240

APA

Kishioka, S; Morita, N; Kitabata, Y; Yamanishi, T; Miyamoto, Y; Ozaki, M; Yamamoto, H. (1992). Dynorphin-(1-13): antinociceptive action and its effects on morphine analgesia and acute tolerance.. Japanese journal of pharmacology, 60(3), 197-207.

MLA

Kishioka, S, et al. "Dynorphin-(1-13): antinociceptive action and its effects on morphine analgesia and acute tolerance.." Japanese journal of pharmacology, 1992.

RethinkPeptides

RethinkPeptides Research Database. "Dynorphin-(1-13): antinociceptive action and its effects on ..." RPEP-00240. Retrieved from https://rethinkpeptides.com/research/kishioka-1992-dynorphin113-antinociceptive-action-and

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.